Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study

European Psychiatry

Volumn 23, Issue 1, 2008, Pages 66-73

  Bauer, Michael ^a   Monz, Brigitta U ^b   Montejo, Angel L ^c   Quail, Deborah ^d   Dantchev, Nicolas ^e   Demyttenaere, Koen ^f   Garcia Cebrian, Ana ^d   Grassi, Luigi ^g   Perahia, David G S ^d,h   Reed, Catherine ^d   Tylee, Andre ⁱ  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e HÔTEL DIEU   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF FERRARA   (Italy)

^h Gordon Hospital   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressants; Depression; Europe; FINDER; Prescribing patterns

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGE; AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG CHOICE; EDUCATIONAL STATUS; EUROPE; FEMALE; GENERAL PRACTITIONER; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MONOTHERAPY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SMOKING;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CROSS-CULTURAL COMPARISON; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; EUROPE; GERMANY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; RECURRENCE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 39149132483     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.11.001     Document Type: Article

References (38)

1. Agüera L.F., Rojo J.E., Ros S., de la Gándara J., and de Pedro J.M. Antidepressant combinations: epidemiological considerations. Acta Psychiatr Scand 112 Suppl. 428 (2005) 7-10
2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 Suppl. 4 (2000) 1-45
3. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58 (2000) 19-36
4. Anderson I.M., Nutt D.J., and Deakin J.F.W. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 14 (2000) 3-20
5. Arroll B., Macgillivray S., Ogston S., Reid I., Sullivan F., Williams B., et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3 (2005) 449-456
6. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8 (2007) 67-104
7. Bauer M., Whybrow P.C., Angst J., Versiani M., and Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3 (2002) 5-43
8. Bauer M., Whybrow P.C., Angst J., Versiani M., and Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3 (2002) 69-86
9. Brooks R., and with the EuroQoL Group. EuroQol: the current state of play. Health Policy 37 (1996) 53-72
10. Claxton A.J., Li Z., and McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry 177 (2000) 163-168
11. De la Gandara J., Aguera L., Rojo J.E., Ros S., and de Pedro J.M. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand 112 Suppl. 428 (2005) 32-36
12. ESEMeD/MHEDEA 2000 Investigators. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 109 Suppl. 420 (2004) 55-64
13. Fegert J.M., Kolch M., Zito J.M., Glaeska G., and Jahnsen K. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16 (2006) 197-206
14. Furukawa T.A., McGuire H., and Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 325 (2002) 991-1000
15. Garcia-Cebrian A., Bauer M., Montejo A.L., Dantchev N., Demyttenaere K., Gandhi P., et al. Characteristics of depressed outpatients entering the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 23 (2008) 57-65
16. Guaiana G., Andretta M., Corbari L., Mirandola M., Sorio A., D'Avanzo B., et al. Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. J Clin Psychiatry 66 (2005) 750-755
17. Hansen R.A., Gartlehner G., Lohr K.N., Gaynes B.N., and Carey T.S. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143 (2005) 415-426
18. Lawrenson R.A., Tyrer F., Newson R.B., and Farmer R.D. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59 (2000) 149-157
19. MacGillivray S., Arroll B., Hatcher S., Ogston S., Reid I., Sullivan F., et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326 (2003) 1014-1019
20. Martin-Agueda B., Lopez-Munoz F., Rubio G., Guerra J.A., Silva A., and Alamo C. Management of depression in primary care: a survey of general practitioners in Spain. Gen Hosp Psychiatry 27 (2005) 305-312
21. Montejo A.L., Gilaberte I., Fombellida C., Hylan T.R., and Sacristan J.A. Pattern of usage of new antidepressants in clinical practice. Actas Luso Esp Neurol Psiquiatr 26 (1998) 75-81 [in Spanish]
22. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline No. 23 (December 2004). http://www.nice.org.uk/ Available from www.nice.org.uk [accessed 4.12.2007]
23. Olie J.P., Elomari F., Spadone C., and Lepine J.P. Antidepressant consumption in the global population in France. Encephale 28 (2002) 411-417 [in French]
24. Paykel E.S., Brugha T., and Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 15 (2005) 411-423
25. Peretti S., Judge R., and Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand 102 Suppl. 403 (2000) 17-25
26. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354 (2006) 1231-1242
27. Sclar D.A., Robison L.M., Skaer T.L., and Galin R.S. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. Int J Psychiatry Med 28 (1998) 407-419
28. Sleath B., and Shih Y.C. Sociological influences on antidepressant prescribing. Soc Sci Med 56 (2003) 1335-1344
29. Stafford R.S., MacDonald E.A., and Finkelstein S.N. National patterns of medication treatment for depression, 1987 to 2001. Primary Care Companion J Clin Psychiatry 3 (2001) 232-235
30. Tylee A., Gastpar M., Lepine J.P., and Mendlewicz J. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. Int Clin Psychopharmacol 14 (1999) 139-151
31. Ufer M., Meyer S.A., Junge O., Selke G., Volz H.P., Hedderich J., et al. Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription based analysis. Pharmacoepidemiol Drug Saf 16 (2007) 1153-1160
32. Van Marwijk H.W., Bijl D., Ader H.J., and de Haan M. Antidepressant prescription for depression in general practice in The Netherlands. Pharm World Sci 23 (2001) 46-49
33. Williams J.W., Mulrow C.D., Chiquette E., Hitchcock P., Aguilar C., and Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 132 (2000) 743-756
34. Wohlreich M.M., Martinez J.M., Mallinckrodt C.H., Prakash A., Watkin J.G., and Fava M. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 25 (2005) 552-560
35. Zetin M., Hoepner C.T., and Bjornson L. Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull 39 (2006) 38-104
36. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983) 361-370
37. Zimmerman M., Mattia J.I., and Posternak M.A. Are subjects in pharmacological treatment trials for depression representative of patients in routine clinical practice?. Am J Psychiatry 159 (2002) 469-473
38. Zimmerman M., Posternak M., Friedman M., Attiullah N., Baymiller S., Boland R., et al. Which factors influence psychiatrists' selection of antidepressants?. Am J Psychiatry 161 (2004) 1285-1289